NCT02991885 - HAL-MPE1 Safety and Tolerability Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

April 30, 2019

Study Completion Date

September 30, 2019

Conditions

Peanut Allergy

Interventions

BIOLOGICAL

HAL-MPE1

Weekly subcutaneous administrations of HAL-MPE1

DRUG

HAL-MPE1 placebo

Weekly subcutaneous administrations of HAL-MPE1 placebo

Trial Locations (7)

Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York

John Hopkins Hospital University-Divison of Pediatric Allergy, Baltimore

UNC Rheumatolory Allergy & Immunology Clinic, Chapel Hill

Allergy, Asthma and Immunology Center, Tulsa

South Texas Allergy & Asthma Medical Professionals (STAAMP), San Antonio

Asthma, Inc., Seattle

Inflamax Research Limited, Mississauga